secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009899
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma reaffirms FY2025 total revenue guidance at JPM conference
---------------------------------------------------------------------

- Expects to meet previously announced total revenue guidance range for FY2025 year ended Dec 31, 2025.
- Provided revenue expectations for Xywav, Epidiolex, and Modeyso for the full year 2025.
- Presentation delivered at 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312526009899/0001193125-26-009899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312526009899/d61589d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer